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Sllmmary 
Lipopolysaccharides (LPS) that lack acyloxyacyl groups can antagonize responses to LPS in human 
cells. Although the site and mechanism of inhibition are not known, it has been proposed that 
these inhibitory molecules compete with LPS for a common cellular target such as a cell-surface 
binding receptor.  In the present study, we used an in vitro model system to test this hypothesis 
and to evaluate the role of CD14 in cellular responses to LPS. Cells of the THP-1 human monocyte- 
macrophage cell line were exposed to 1,25 dihydroxyvitamin D3 to induce adherence to plastic 
and expression of CD14, a binding receptor for LPS complexed with LPS-binding protein (LBP). 
The uptake of picograms of [3H]LPS (agonist) and enzymatically deacylated LPS [3H]dLPS 
(antagonist) was measured by exposing the cells to the radiolabeled ligands for short incubation 
periods. The amounts of cell-associated LPS and dLPS were then correlated with cellular responses 
by measuring the induction of nuclear NF-KB binding activity and the production of cell-assodated 
interleukin (IL)-IB. We found that similar amounts of [3H]LPS or [3H]dLPS were taken up by 
the cells. The rate of cellular  accumulation of the ligands was greatly enhanced by LBP and 
blocked by a monoclonal antibody to CD14 (mAb 60b), yet no cellular responses were induced 
by dLPS or dLPS-LBP complexes. In contrast, LPS stimulated marked increases of NF-rB binding 
activity and Ibl~.  These responses were enhanced by LBP and inhibited by mAb 60b.  dLPS 
and its synthetic lipid A counterpart, LA-14-PP (also known as lipid Ia, lipid IVa, or compound 
406) strongly inhibited LPS-induced NF-KB and IL1B, yet neither antagonist inhibited the uptake 
of LPS via CD14. dLPS did not inhibit NF-KB responses to tumor necrosis factor (TNF)c~ or 
phorbol ester. Our results indicate that (a) both stimulatory and nonstimulatory ligands can 
bind to CD14 in the presence of LBP; (b) the mechanism of inhibition by dLPS is LPS-specific, 
yet does not involve blockade of LPS binding to CD14; and (c) in keeping with previous results 
of others, large concentrations of LPS can stimulate the cells in the absence of detectable binding 
to CD14. The findings indicate that the site of dLPS inhibition is distal to CD14 binding in 
the LPS signal pathway in THP-1 cells, and suggest that molecules other than CD14 are important 
in LPS signaling. 
nimals have sensitive mechanisms for recognizing and re- 
sponding to gram-negative bacterial LPS (also called en- 
dotoxin). Several cellular mechanisms for binding LPS have 
been described (1-8)  and recent evidence suggests that the 
uptake of LPS by cells of monocytic origin (macrophages, 
monocytes) or neutrophils is linked to LPS recognition and 
cellular responses. However, the relationships between LPS- 
binding proteins in the cell membrane and signaling pathways 
are not understood. 
CD14, a glycosylphosphatidylinositol-anchored  protein ex- 
pressed on the surface of monocytes, macrophages, and acti- 
vated neutrophils (9-11),  has been shown to be a receptor 
for complexes of LPS and LPS-binding protein (LBP) 1 (8, 
12). Laboratory studies with isolated monocytes, neutrophils, 
1 Abbreviations used in this paper: AOAH,  acyloxyacyl hydrohse;  dLPS, 
enzymatically deacylated LPS lacking secondary fatty acyl chains; DTT, 
dithiothreitol; EMSA, electrophoretic  mobility shift assay;  LBP, LPS-binding 
protein; LPS-LBP and dLPS-LBP, complexes  of LPS and dLPS, respectively, 
with LBP. 
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Volume 176  August 1992  485--494 freshly  drawn  whole blood  ex  vivo  (8,  12),  and  CD14- 
transfected 70Z/3 cells (13) support the contention that the 
LBP/CD14-dependent pathway is closely linked to initiation 
of cellular responses. Two models have been proposed to ex- 
plain how this pathway might function in LPS signaling (1, 
2). In the first modal, LPS binding to CD14 directly stimu- 
lates the cell, whereas in the second, the CD14-LPS interac- 
tion facilitates  the subsequent interaction  of LPS with an- 
other signaling molecule. A direct signaling role for CD14 
is suggested by reports that certain anti-CD14 mAbs can mimic 
some of the effects of LPS in human monocytes (14, 15). The 
second model is supported by the observation that increasing 
concentrations of LPS can overcome the ability of blockade 
or depletion of CD14  to inhibit  TNFol production  (8). 
The study of lipid A analogs that can function as LPS an- 
tagonists should provide useful information  about the LPS 
signal pathway. One such analog is produced by the leuko- 
cyte enzyme,  acyloxyacyl hydrolase (AOAH),  which selec- 
tively removes secondary acyl chains from the lipid A region 
of LPS (16, 17). Several laboratories have reported that enzy- 
matically deacylated LPS (dLPS) (18-21) and its lipid A coun- 
terpart (known variously as synthetic analogs LA-14-PP or 
406, or biosynthetic precursors Ia or IVa) (21-26) can inhibit 
the ability of LPS or lipid A  to stimulate human cells. Al- 
though most investigators have assumed that  these inhibi- 
tors compete with LPS for a common cellular target mole- 
cule,  the  site and mechanism  of inhibition  have not  been 
determined. 
In this paper we describe the uptake of picograms of bio- 
synthetically radiolabeled Escherichia  coli LPS and dLPS by 
the human monocyte-macrophage cell line, THP-1. (The term 
"uptake" is used here to refer to the association of LPS with 
the cell and is a measure of both membrane-bound and inter- 
nalized LPS.) The uptake of both of these ligands was en- 
hanced in the presence of LBP and blocked by a mAb to CD14. 
LBP also enhanced the ability of LPS to induce NF-KB and 
Iblf3 responses by these cells, but neither dLPS nor dLPS- 
LBP triggered these responses. Remarkably, dLPS-LBP and 
LA-14-PP-LBP inhibited responses to LPS-LBP without di- 
minishing LPS uptake by the cells. These observations indi- 
cate that CD14 can participate in the cellular uptake of both 
stimulatory (LPS) and nonstimulatory (dLPS) ligands. More- 
over, the mechanism of inhibition by dLPS does not involve 
inhibition  of LPS binding to CD14.  Our data suggest that 
dLPS may block the binding of LPS to a low-abundance fig- 
naling molecule, or that  the uptake of dLPS may initiate a 
negative signal that counteracts or blocks the LPS signal to 
the cell. 
Materials  and Methods 
Cell Cultur~  THIXl cells were obtained from Dr. Dario C. AI- 
tieri (The Scripps Research Institute, LaJolla, CA) and were grown 
in RPMI-1640 with 7% fetal bovine serum (heat-inactivated at 56~ 
for 30  rain)  (Hyclone  Laboratories  Inc.,  Logan,  UT),  2  mM 
L-glutamine, 50 U/ml penicillin G, and 50/~g/ml streptomycin in 
a 5% COz atmosphere at 37~  To minimize cell variability, the 
cells were revived from frozen stock every 2-3 too. To induce ad- 
herence to plastic and expression of CD14, cukures were grown 
in 6-well plates (Costar, Cambridge, MA) in the presence of 0.1/~M 
1,25-dihydroxy  vitamin  D3  (Biomol  Res.  Laboratories, Inc., 
Plymouth Meeting, PA). After 72 h, cultures were fed by adding 
0.5 vol of medium containing  vitamin D3 and incubated for an- 
other 24 h. 
Antibodies and Reagents.  Anti-CD14 mAbs, 60b (IgG1) (27) and 
26ic (IgG2b) (28), were kindly provided by Robert F. Todd (Univer- 
sity of Michigan, Ann Arbor). Anti-CD18 mAb, 60.3 (IgG2a) (29), 
was kindly provided by  John M. Harlan (University of Washington, 
Seattle). Antibodies in ascites fluid were titrated either by FACS  | 
analysis (Becton Dickinson & Co., Mountain View, CA) of binding 
to THP-1 cells, or by their ability to block LPS uptake (mAb 60b). 
They were used at 1:500 dilution in the experiments reported here. 
Nonimmune control antibody used for FACS* analysis (Becton 
Dickinson & Co.) was a mixture of 2 #g/ml each of routine IgG1, 
2a, 2b, and 3 isotypes (Coulter Immunology,  Hialeah, FL), and 
FITC-labeled F(ab')2 fragments of goat anti-mouse IgG (H +  L) 
were from Tago, Inc. (Burlingame, CA). LBP, purified from rabbit 
acute phase serum,  was generously provided by Peter S. Tobias 
(Scripps Clinic and Research Foundation,  La Jolla, CA). Optimal 
amounts of LBP were determined  empirically by measuring LPS 
uptake using each lot of LBP. Tissue culture-tested, endotoxin-tested 
(0.005 ng endotoxin/mg) BSA was obtained from Sigma Chem- 
ical Co. (St. Louis, MO). Double-stranded  poly(dI-dC)  was ob- 
tained  from Pharmacia Fine Chemicals  (Piscataway, NJ).  Strict 
pyrogen-free conditions were maintained by using sterile dispos- 
able plasticware and pipette tips, and pyrogen-free distilled water 
(Baxter Healthcare  Corp.,  Deerfield, IL). 
LPS and Lipid A  Preparations.  E. coli LCD25, a K12 derivative 
with Ra or Rb LPS core structure,  was biosynthetically radiola- 
beled with [3H]acetate as described (30). Its sp act was 4,200 3H 
dpm/ng,  and essentially all of the radioactivity was in the fatty 
acyl chains. The radiohbeled LPS was deacylated  using AOAH (19). 
Sp act of the dLPS preparations used were 2,885 and 3,020 dpm/ng. 
Both deacyhted and mock-treated LPS were suspended (100/zg/ml) 
in 0.9% NaC1 with 5 rag/m1 BSA and stored at  -70~  Nonra- 
dioactive dLPS was produced from E. coli J5 LPS by using trace 
amounts of [3H]LPS to follow the extent of deacylation. Samples 
containing deacylation reaction components without LPS ("mock 
dLPS') were used as controls. Synthetic lipid LA-14-PP from ICN 
Biomedicals, Inc. (Cleveland, OH), was suspended in PBS, soni- 
cated, and stored (0.5 mg/ml) at  -70~  Before use, an aliquot 
of each LPS or LA-14-PP preparation  was diluted to 2/zg/ml in 
RPMI-1640 containing  0.5 mg/ml BSA and sonicated for 1 s on 
low power with a sonifier with a small steel probe (model 450; 
Branson Ultrasonics Corp.,  Danbury,  CT), and the radioactivity 
in the sample was counted. LPS-LBP complexes were prepared by 
mixing  aliquots of sonicated LPS with LBP immediately before 
use (typically a 10-fold excess of LBP by weight was used for LPS 
and dLPS, and a 30-fold excess was used for LA-14-PP), incubated 
10 min at 37~  diluted with RPMI/BSA to the working concen- 
tration, and kept at room temperature until used. Tritium counting 
was performed in a liquid scintillation counter (Tricarb 4000 Minaxi; 
Packard, Downers Grove, IL) with external standardization  and 
quench correction. 
Cell Stimulation.  96-h cultures  of vitamin  D3-treated THP-1 
cells were prepared in 6-well plates as described above. Nonadherent 
cells were removed by washing with RPMI, and incubations were 
performed in the absence of serum using 1 ml of RPMI containing 
penicillin, streptomycin,  glutamine,  and 0.5 mg/ml BSA. Addi- 
tions of LPS and other reagents were made in 10-100/zl volumes. 
After incubation, cells were washed at room temperature once with 
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of PBS. Cells were then placed on ice until addition of buffer A 
(see below). Assays for uptake, NF-gB, Iblfl, and protein were per- 
formed in each experimental sample as described bdow. Each data 
point represents the mean value of duplicate wells, and error bars 
are shown in the figures when the range of  the duplicates exceeded 
the size of the markers. Each observation was repeated at least three 
times with similar results. 
Nuclear Extracts and Cell Lysates.  The nuclear extract for NF-~B 
assay and the ceil lysate for assay of  ceil-associated  IL-lfl and uptake 
of radiolabeled LPS were prepared from the same experimental 
sample by a micro-extraction  protocol modified from previous 
methods 01). Adherent THP-1 ceils (typically 10  ~  ceils/well) were 
lysed by adding I ml/well of cold buffer A (10 mM Hepes pH 7.9, 
1.5 mM MgClz, 10 mM KC1, 0.5 ram dithiothreitol [DTT], 0.5 
mM PMSF, and 0.1% (wt/vol) NP-40; PMSF and DTT were added 
freshly before use). The cell lysate was mixed in an osdlhting ice 
bath for 5-10 rain and transferred to a microcentrifuge tube. Nuclei 
were pelleted by centrifugation  at 750 g for 5 min at 4~  and 
an aliquot (typically 0.5 nil) of supernatant was removed for scin- 
tillation  counting (LPS uptake).  Another aliquot was stored at 
-70~  for IL-lfl assay and the residual supematant was aspirated. 
The nuclear pellet was vortexed in 15 #1 of buffer C and allowed 
to stand in ice for 30 n'fin, vortexing at 10-rain intervals~ Buffer 
C consisted of  20 mM Hepes, pH 7.9, 25% glycerol (vol/vol), 420 
mM NaC1, 1.5 mM MgC12, 0.2 mM EDTA, 0.5 mM DTT, and 
0.5 mM PMSF. Nuclear extracts were centrifuged at 12,000 g for 
10 rain. Each supernatant was removed, mixed with 15 ~1 of  buffer 
D (10 raM Tris ((21) pH 7.5, 0.2 mM EDTA, 1% NP-40, 0.5 mM 
DTT, and 0.5 mM PMSF), and stored at  -70~ 
NF-JcB Assay.  Nuclear NF-gB was measured by electrophoretic 
mobility shift assay (EMSA) by modification of a previous method 
(32). 10 #1 nuclear extract (typically 4-5/~g protein) were mixed 
with 5 #1 of  a reaction mixture that contained, in 15 #1 final volume, 
10 mM Tris(C1), pH 7.5, 50 mM NaC1, I mM DTT, 1 mM EDTA, 
5% glycerol, I rag/m1BSA, and 0.1 rag/m1 double-stranded  poly(dI- 
dC). After standing on ice 15 rain, 5 #1 of 32P-labeled oligonucle- 
otide (typically 0.2 ng and 50,000 Cerenkov ~m) was added and 
allowed to stand at room temperature for 20 rain.  2 #1 of 0.1% 
bromphenol blue was added, and 10 gl of the mixture was loaded 
onto a 4% polyacrylamide mini-gel (7 cmx  8 era  x  1 ram) that 
had been prerun for 30 re_in. Electrophoresis was for I h at 72 V 
in running buffer (6.7 mM Tris(Cl) pH 7.5, 3.3 mM sodium ace- 
tate and  1.0 mM EDTA). The gel was dried onto paper under 
vacuum  at  80~  for 1 h  and visualized by exposure to Kodak 
X-OMAT AK film (Eastman Kodak Co., Rochester, NY). Retarded 
bands were cut from the dried gel and Cerenkov cpm were mea- 
sured by counting in distilled water on an open tritium channel. 
"Relative NF-gB" refers to the increase in cpm/#g nuclear extract 
protein above the unstimulated control (e.g., relative NF-gB  =  2 
indicates a value that is twofold higher than the control). The NF-KB 
oligonucleotide, 
5' GTTCGACAGAGGC~ACTTTCCGAGAGG  Y 
3'  TGTCTCCCCTGAAAGC~TCTCCGTTG 5' 
was prepared from synthetic oligonucleotides as a double-stranded 
31 mer with 26 bp corresponding  to the wild-type murine ~ L 
chain enhancer sequence (33). 32p labeling was performed with 
ot-[3zP]dCTP or dATP using Khnow fragment.  The labeled oli- 
gonudeotide was purified by successive  passes over two Sephadex 
G-50 spin columns (Pharmada Fine Chemicals). 
ILl, Assay.  Ceil-associated  IDlfl was measured  by ELISA  using 
the high-sensitivity  IL-lfl kit from Cistron Biotechnology  (Pine 
Brook, NJ). 100 ~1 of postnuclear supernatant was used undiluted 
or diluted in buffer A. The lower limit of detection of II,  lfl was 
15-20 pg/ml. 
Protein Assay.  Cell number per well was routinely determined 
by protein quantitation  using Coomassie Protein Assay Reagent 
(Pierce Chemical Co., Rockford, IL) in the manufacturer's micro- 
titer protocol. BSA diluted in the appropriate NP-40-containing 
diluent was used as a standard. Correlation of protein content with 
cell number was done in separate experiments by resuspending ad- 
herent ceils in cold PBS, counting in a hemocytometer, and as- 
saying for protein in the presence of  NP-40 as described above. One 
million cells contained "~275 #g of protein. 
FACS  ~ Analysis.  Cell-surface expression of CD14 was deter- 
mined by suspension staining with appropriately diluted anti-CD14 
mAb, nonimmune ascites or control IgG. Antibody solutions con- 
tained 1% normal goat serum for blocking. Bound mAb was de- 
tected with FITC-labded F(ab')z fragments  of goat anti-mouse 
IgG (H + L). Flow cytometry was performed  by a FACScan  |  (Becton 
Dickinson  & Co.,  San Jose, CA). 
Results 
Vitamin D3 Induces CD14 Expression and Adherence to Plas~ 
THP-1,  a  human  leukemia  cell  line  of  the  monocyte- 
macrophage lineage (34), was used as a modal system for the 
present study. Although untreated THP-1 ceils are not ad- 
herent and express little or no cell-surface CD14, exposure 
to 1,25-dihy&oxyvitamin D3-induced adherence to plastic 
and expression of high levels of cell-surface CD14 (35) (Fig. 
1). CD14 expression increased over time, reaching a level of 
~,1-2  x  106 molecules/cell by 72 h  of culture in vitamin 
D3 (Peter S. Tobias, personal communication). Greater than 
95% of adherent cells expressed CD14 as detected by mAbs 
60b  and  26ic.  Stimulation with  LPS for <1  h  induced a 
z  I" ~  ./~ 
--  /  t  ./ 
/  /i 
Log  Fluorescence  Intensity 
Figure 1.  Surface  e~pression  of  CD14 on THlXl cells: effect  of  vitamin 
D3. THP-1 cells were incubated for 96 h in complete  medium with 0.1 
#M vitamin D3. Nonadherent  cells were removed  and the adherent cells 
were resuspended  in cold PBS and stained in suspension  using mAb 60b, 
control antibody, or nonimmune mouse ascites. An equivalent number 
of cells not treated with vitamin  D~ was stained as above  with 60b. Histo- 
grams from the same e~periment  were overbid. (--...) Vitamin D3-treated 
cells stained with 60 b; (- ￿9 .) control antibody; or (---) nonimmune  as- 
cites. (  ) Untreated cells stained with 60b. 
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many adherent cells. 
LPS  Uptake  The availability  of [3H]LPS labeled  to  a 
high specific activity (4.2  x  10  ~ dpm//~g) provided a unique 
opportunity to measure the uptake of LPS under conditions 
that were near the dose threshold for cellular responses. Twice 
the counting background (63 dpm) is equivalent to 15 pg 
[3H]LPS. Assuming an average of 10  ~ cells/well and an av- 
erage molecular mass of 4,000 kD for the LPS monomer, 
this represents 2,250 molecules of LPS per cell.  The term 
"uptake" refers to cell-associated radioactivity derived from 
[~H]LPS or [3H]dLPS after incubation at 37~  The loca- 
tion of the cell-associated  ligands on or in the cell is not known. 
In studies not shown here, we found that <15% of the fatty 
acyl chains are removed from the LPS by cellular deacylation 
during the short incubation periods used here,  suggesting 
that most of the cell-associated radioactivity is in intact LPS. 
Ligand-binding studies were not done at 4~  since significant 
LP$ binding could not be demonstrated at this temperature 
(data  not shown). 
NF~cB and 11..I,8 Responses.  To correlate  the uptake of 
[3H]LPS with a quantifiable early activation marker, we used 
a micro-assay for nuclear NF-xB binding activity. The NF-KB 
response under various conditions is shown in Fig. 2 A. Un- 
stimulated THP-1 cells expressed low levels of NF-xB (lane 
1), and a 1-h incubation with LPS-LBP stimulated a marked 
increased in NF-xB above control levels (lanes 4 and 5). By 
contrast, dLPS-LBP did not stimulate NF-xB (lanes 2 and 
3).  As anticipated, dLPS was also an effective inhibitor of 
the NF-xB response to LPS (lane 6). This antagonistic effect 
appeared  to be specific for LPS since dLPS did not inhibit 
the NF-xB response to TNFo~ (lanes 7 and 8) or to phorbol 
ester (lanes 9 and 10). Serial dilutions of a nuclear extract 
from LPS-stimulated cells showed good proportionality with 
Cerenkov cpm, and the ability of unlabeled oligonucleotide 
to  block binding of the  labeled  oligonudeotide showed 
specificity  (Fig.  2, B  and C). 
To obtain an independent assessment of cell responses, we 
measured the accumulation of II.-1B in the same experimental 
samples used for LPS uptake and NF-xB assay. The 1-h time 
points used in this study were too early to measure Ibl re- 
lease into the culture medium, but an early response could 
Ri~chen~  Fiqure 3 
Figure 2.  EMSA for nuclear NF-KB in vitamin D3-treated THP-1 cells. 
(A) THP-1 cells (0.8  x  10  ~ calls/well) were stimulated for 1 h at 37~ 
as indicated, and NF-xB was assayed using 4.5/~g nuclear extract protein. 
(I) No addition; (2) 3 ng/ml dLPS-LBP; (3) 30 ng/ml dLPS-LBP; (4) 0.1 
ng/ml LPS-LBP; (5) 3 ng/ml LPS-LBP; (6) 3 ng/ml LPS-LBP  +  3 ng/ml 
dLPS-LBP; (7) 10 pM TNF-c~; (8) 10 pM TNFot  +  3 ng/ml dLPS-LBP; 
(9) 50 nM PMA; and (10) 50 nM PMA +  3 ng/ml dLPS-LBP. An autora- 
diogram of the dried gel is shown.  (B) Cells were incubated for 1 h at 
37~  with 3 ng/ml LPS-LBP, and pooled nuclear extracts were prepared 
in duplicate twofold serial dilutions (10 #1 undiluted extract =  5/zg pro- 
tein). The far right lane (X) represents undiluted extract containing a 100- 
fold excess (25 ng) of unlabeled competitor oligonucleotide. (C) NF-KB 
bands were cut from lanes in B, np was measured by Cerenkov counting, 
and the cpm were plotted against the amount of nuclear extract used. 
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Figure 3.  [3H]LPS dose-response: effect of LBP and anti-CD14 mAb 
60b on LPS uptake, nuclear NF-gB, and cell-associated II~1~. Vitamin D3- 
treated THP-1 cells (10~ cells/well) were preincubated at 10-15~  with 
or without mAb 60b for 15 rain. Calls were warmed to room temperature 
and varying amounts of [3H]LPS or [3H]dLPS (in 10-100/~1 vol) were 
added and incubated for 1 h at 37~  (/t) Uptake of LPS-LBP. (J--i) 
LPS-LBP; (O---O) LPS-LBP +  60b; and (....) Nonspecific binding of LPS- 
LBP  to  plastic.  (B)  NF-xB  response.  (i--I)LPS-LBP;  and  (0---(9) 
LPS-LBP  +  60b.  (C)  IL-I~ response. (B--i)  LPS-LBP;  and (O---O) 
LPS-LBP  +  60b.  (D) Uptake of LPS without LBP. (ig--I) LPS;  (O) 
LPS  +  60b;  and (..-.) Nonspedfic binding to plastic in wells with cells 
removed. (E) NF-xB response. (B---i) LPS; and (O---O) LPS  +  60b. (F) 
ID1B response.  (i---i) LPS; and (O---O) LPS  +  60b. 
488  CD14-mediated Responses  to Lipopolysaccharides be measured in cell lysates. Although at I  h the IL-1B levels 
induced by LPS were low (100-500 pg/106 cells compared 
with 25-35 pg/106 cells in unstimulated controls) and varied 
in separate experiments, the measurements were internally 
consistent within each experiment. 
LBP Augments the Uptake of  LPS and Increases  LPS-induced 
NF-KB and II.,I~ Responses.  As shown in Fig. 3, A  and D, 
LBP increased the uptake of LPS by the cells. NF-gB binding 
activity was increased by LBP throughout the dose range from 
0.1 to 10 ng/ml LPS (Fig. 3, B and E), and an Ibl/3 response 
was observed only in the presence of LBP (Fig. 3, C and F). 
Anti-CD14 mAb 60b Blocks Uptake of LPS but Does Not 
Completely Prevent Cell Responses.  Also shown in Fig. 3, A 
and D is the impact ofmAb 60b on LPS uptake. 60b blocked 
all detectable uptake of LPS, whether or not it was complexed 
with LBP. By contrast, Table 1 shows that uptake was not 
inhibited by mAb 26ic, previously reported to be a nonblocking 
antibody to CD14 (8), or by anti-CD18 mAb 60.3. Virtu- 
ally all of the residual uptake observed after blocking with 
60b could be accounted for by nonspecific adherence of LPS 
to plastic (Table I  and Fig. 3, A  and D). In control experi- 
ments,  6-well plates were either incubated with complete 
medium without cells for 96 h, or adherent cells were re- 
moved from the wells by vigorous washing.  [3H]LPS-LBP 
was then added to the wells, the plates were incubated for 
1 h  at 37~  and residual 3H was measured after washing 
the wells and adding detergent lysis buffer as described in 
Materials and Methods.  In wells that had been incubated 
without cells, the average binding was 0.13%  +  0.05% SD 
(n  =  3) of the added [3H]LPS.  [3H]LPS binding was only 
slightly higher (0.28%  +  0.06%  SD, n  =  6)  when cells 
had been removed from the plates by washing. For compar- 
ison,  the uptake of LBP-bound [3H]LPS by adherent cells 
averaged 11%  +  4%  SD (n  =  26) of the added [3H]LPS. 
Table  1.  Effect of mAbs on Uptake and Response 
NF-gB 
Uptake  (Relative)  IL-1B 
(pg  / l O~ cells)  (pg  / l O~ cells) 
LBP alone 
No  Ab  -  1.0  _+ 0.05  26 •  2.5 
60b (o~CD-14)  -  0.6  +  0.03  29  •  0.5 
26ic (c~CD-14)  -  0.8  +  0.02  24  •  0 
60.3  (~CD-18)  -/  1.0  +_  0.20  27  •  0 
[3H]LPS:LBP 
No Ab  393  •  3  5.3  •  0.15  273  +  45 
60b (c~CD-14)  7  +  2  1.7  _+ 0.09  20  :t:  1 
26ic (c~CD-14)  350  •  16  5.3  •  0.33  282  •  14 
60.3  (o~CD-18)  344  •  26  5.8  •  0.10  246  •  16 
Nonspecific*  8  -  - 
[3H]dLPS:LBP 
No Ab  366  •  5  1.1  +  0.03  23  •  2 
60b (c~CD-14)  19  •  2  0.7  •  0.04  30  •  0.5 
26ic (otCD-14)  306  •  11  0.9  +_ 0.15  27  +  4 
60.3  (o~CD-18)  303  •  5  1.1  •  0.08  26  +_  0.5 
Nonspecific*  14  -  - 
[3H]dLPS:LBP +  [3H]LPS:LBP 
No Ab  797  +_  3*  1.7  •  0.10  56  +  1 
60b (c~CD-14)  27  •  0.5*  2.0  •  0.06  12  •  12 
Vitamin D3-treated THP-1 ceils (1.1  x  106 cells/well) were preincubated at 10-15~  with or without mAb for 15 min. Cells were warmed to 
room temperature  and 3 ng/ml (50/zl) of [3H]LPS:LBP  or [3H]dLPS:LBP,  or 3 ng/ml each of [3H]LPS:LBP +  [3H]dLPS:LBP  were added and 
incubated for 1 h at 37~ 
* Nonspecific binding to plastic: cells were removed from wells by washing before incubation with labeled compounds as described above. 
Uptake in dpm from both labeled compounds was ~  equal to the sum of the uptake of the individual compounds. Conversion to pg/106 cells 
is based on the average specific radioactivity  of the two compounds. 
489  Kitchens  et al. This was reduced to 0.35%  + 0.14% (n = 8) after blocking 
with mAb 60b. 
As shown in Fig. 3, B and E, mAb 60b greatly reduced 
cellular responses to LPS. The NF-xB response was suppressed 
by 60b at low LPS concentrations  (0.1-1 ng/ml), but this 
inhibition was partially overcome at 3 and 10 ng/ml, mAb 
60b also suppressed the Iblfl response (Fig. 3 C). 
dLPS Uptake Is A ~o Enhanced by LBP and Blocked by mA b 
60It  Fig. 4 shows dose-response curves for [3H]dLPS and 
[SH]LPS uptake,  in the presence and absence of a 10-fold 
excess of  LBP. LBP greatly enhanced the uptake of  both com- 
pounds. Optimal amounts of each batch of purified LBP were 
determined empirically. It was typical for a 5- to 10-fold  excess 
(by weight) of LBP to produce maximal uptake when prein- 
cubated  in concentrated solution with LPS or dLPS (see 
Materials and Methods). Using LPS-LBP or dLPS.-LBP com- 
plexes preformed at a ratio of 1:10, LBP increased LPS up- 
take 5.3 fold (_+ 2.6 SD, n  =  22) and dLPS uptake 4.2 fold 
(__  1.2 SD, n  =  6). Fig. 4 also shows that, as for LPS (A), 
the uptake of dLPS (B) was inhibited by 60b, whether or 
not the dLPS was complexed with LBP. 
The time course for uptake of [3H]dLPS-LBP was nearly 
identical to that of [3H]LPS-LBP (Fig. 5 A). 
LPS Induces  Nuclear  NF-~cB  Binding  Activity  and Cell-associated 
Ibl/Y. dLPS Does Not.  LPS was a potent stimulus to NF-gB 
binding activity and Iblfl synthesis, but dLPS did not elicit 
either of these responses (Figs. 2 and 3, and Fig. 5, B and 
C). Since  the uptake of  dLPS was enhanced  by LBP and blocked 
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Figure 4.  Dose-response:  effect of LBP and anti-CD14 mAb 60b on 
the uptake of [SH]LPS and [SH]dI,  PS. Vitamin Ds-treated THP-1  cells 
(10  s cells/weft) were preincubated at 10-15~  with or without 60b for 
15 min. Cells were warmed to room temperature and varying amounts 
of radiolabeled ligand (10-100/~1)  were added and incubated for 1 h at 
37~  LPS-LBP  and dLPS-LBP denote prdormed comple~s made by Frdn  - 
cubation of a 2 #g/ml solution of [SH]LPS or [SHldLPS with 20 #g/m1 
LBP for 10 min at 37~ 
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Figure 5.  Time course  for  [SH]LPS 
and  [3H]dLPS uptake  and  responses. 
Vitamin Ds-treated THP-1 cells (0.7  x 
106 cells per well) were incubated with 
3 ng/ml [SH]LPS-LBP or [SH]dLPS-LBP 
for 15, 30, 60, 120, and 180 rain at 37~ 
by mAb 60b, consistent with uptake via CD14, this observa- 
tion indicates that engaging CD14 with an LBP-complexed 
ligand does not necessarily trigger these cell responses. 
dLPS and LA-14-PP  Inhibit Responses to LPS without  Inhibiting 
LPS Uptake  To characterize the antagonistic effects of LPS 
in terms of both [SH]LPS uptake and cellular response, we 
looked  at the interaction  of unlabeled dLPS and [SH]LPS 
ligands that were each prebound to optimal amounts of LBP 
before they were added to the cells, dLPS-LBP was added 
in varying amounts to three concentrations of [SH]LPS-LBP. 
As shown in Fig. 6, dLPS inhibited NF-xB responses without 
inhibiting LPS uptake. In experiments not shown, when dLPS- 
LBP and LPS-LBP were added to cells in equal concentra- 
tions,  NF-KB levels were inhibited by 66  +  6% SD (n  -- 
9) compared to control levels obtained with LPS-LBP alone, 
yet LPS uptake was not inhibited.  The uptake of [SH]LPS 
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Figure 6,  Inhibition of LPS response by dLPS without inhibition of 
LPS intake. Vitamin Ds-treated THP-1 cells (0.7  x  106 cells/well) were 
incubated with 1, 3, or 10 ng/ml [SH]LPS-LBP with varying amounts 
of unlabeled dLPS-LBP for 1 h at 37~  (~/~ lines withfilled markers) LPS 
uptake. (Bottom,  lines with open marh, rs) Nuclear NF-KB response. (Circles 
with dotted line)  1 ng/ml LPS; (Triangles  with dashed  line) 3 ng/ml LPS; 
and (Squares  with solid line)  10 ng/ml LPS. 
490  CD14-mediated Responses to Lipopolysaccharides that occurred in the presence of dLPS was also inhihitable 
by mAb 60b (Table 1, and data not shown). In experiments 
not shown, when [3H]LPS and dLPS were not prebound to 
LBP but were added directly to cells in incubation medium 
without LBP or with limiting concentrations of LBP, LPS 
uptake was inhibited to a variable extent (<50% inhibition). 
This inhibition was largely overcome as the LBP concentra- 
tion was increased. NF-KB and 11.-1/3 responses were dramat- 
ically inhibited by dLPS in the presence or absence of LBP. 
To eliminate the possibility that inhibition by dLPS is due 
to a biological contaminant in the dIPS preparation, similar 
experiments were performed using LA-14-PP. LA-14-PP is 
a chemically defined, synthetic analog of lipid A which is 
structurally equivalent to the lipid A moiety of dLPS. As 
shown in Fig. 7, LA-14-PP-LBP also inhibited NF-KB and 
II.-1B responses  without inhibiting [3H]LPS-LBP uptake. 
Similar experiments in which [3H]dLPS-LBP was added 
to cells with [3H]LPS-LBP (Table 1) were done to exclude 
the possibility that any characteristics of dLPS inhibition are 
due to unanticipated structural differences between the unla- 
beled E. coli J5 dLPS and the E. coli K12 [3H]LPS. As ex- 
pected, the uptake of each of the labeled ligands was addi- 
tive, cellular responses were inhibited, and mAb 60b blocked 
the uptake of both ligands. Control experiments (not shown), 
in which dLPS was  substituted with "mock dLPS"  (see 
Materials  and Methods), confirmed that the presence of re- 
sidual AOAH in the dLPS preparations did not inhibit the 
ability of LPS to stimulate a cellular response. 
Inhibition by dIPS Is Not a Result of  LPS Sequestration.  Since 
LPS can form aggregates in solution (36, 37), we addressed 
the possibility that dLPS might sequester LPS binding site(s) 
that are important for inducing cell responses. We incubated 
THP-1 cells with varying amounts of dLPS-LBP (0-1 ng/ml) 
for 1 h, washed the cells, and added 3 ng/ml of [3H]LPS- 
LBP. As shown in Fig. 8, preincubation with as little as 0.3 
ng/ml dLPS for I h inhibited the NF-~B response to 3 ng/ml 
LPS by 50%, yet LPS uptake was not inhibited. In experi- 
ments not shown, NF-KB responses to submaximal stimula- 
tory amounts of TNFc~ and phorbol ester were not inhibited 
by dLPS preincubation. 
Discussion 
Two general models have been put forward to account for 
the role of CD14 in cellular  responses  to LPS (1, 2). The 
first model proposes that when LPS or LPS-LBP binds CD14, 
the LPS signal is directly transduced to the cell. In keeping 
with this model, mAbs to CD14 can trigger a number of 
responses in monocytes and nentrophils, including ligand in- 
terualization, transient oxidative burst, Ibl production (14, 
38), homotypic adhesion (15), and calcium fluxes (38). CD14 
itself need not be the signal transducer, however, since the 
signaling molecule might associate with CD14 after initial 
ligand binding (like the interaction of gp130 with IL-6R) (39), 
or may be part of a molecular complex with CD14. Close 
association of CD14 with a protein kinase (40), for example, 
might account for the finding that protein tyrosine phos- 
phorylation is induced as an early response to LPS in murine 
macrophages (41). In the second model, CD14 is not so directly 
involved in signaling. Rather, it binds LPS on the cell mem- 
brane, where the LPS can interact (possibly by transfer within 
the membrane or cell) with the actual signaling molecule(s) 
(1). This model was proposed to account for the observation 
that high LPS concentrations overcome the inhibitory effect 
of blockade or depletion of CD14 on LPS-stimulated TNFc~ 
production (2,  8). 
We found that the binding of both LPS and dLPS to THP-1 
cells was augmented  by LBP and inhibited by anti-CD14 mAb 
60b, indicating that both ligands were interacting with LBP 
and CD14, yet only LPS induced NF-gB and ILI~ responses. 
The ability of LPS and dLPS to associate with the cells in 
the absence of LBP was also inhibited by mAb 60b, suggesting 
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Figure 7.  Inhibition  of LPS response by LA-t4-PP without inhibition 
of LPS uptake. Vitamin D3-tseated THIXl cells (1.1 x  10~ cells/well) were 
incubated with 3 ng/ml [3H]LPS-LBP with varying amounts of unlabeled 
LA-14-PP-LBP for I h at 37~  (Filled squares with solid line) LPS uptake; 
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Figure 8.  Inhibition of LPS response by preincuhation with dLPS. 
Vitamin D3-treated THlXl cells (0.4  x  106 cells/well) were preincubated 
with varying amounts of unlabeled dLPS-LBP for I h at 37~  Cells were 
washed with ILPMI-1640 and incubated with 3 ng/ml [3H]LPS-LBP for 
1 h at 37~  (Filled squares with solid line) LPS uptake; and (Open triangles 
with dashed line) nuclear NF-r,B response. 
491  Kitchens et al. that both ligands may bind directly to CD14, but only LPS 
elicited cell responses. CD14 may therefore bind both stimula- 
tory (LPS) and nonstimulatory (diPS) ligands in THP-1 ceils, 
suggesting that engagement of CD14 is insufficient to pro- 
duce signals resulting in NF-gB binding activity and IL-1t3 
production. 
Another remarkable finding,  that  dLPS and  LA-14-PP 
blocked responses to LPS without inhibiting LPS uptake via 
CD14, seems most consistent with the second model. The 
site of apparent competition between LPS and dips occurs 
after the interaction of LPS with CD14 and might therefore 
involve binding to a low abundance molecule, the putative 
signal transducer.  A different mechanism for dLPS inhibi- 
tion of responses to LPS cannot be excluded, however. Since 
dLPS-LBP is able to inhibit responses to 10-fold or greater 
amounts of LPS-LBP, yet does not block the same responses 
to TNFot or phorbol ester, diPS may be able to induce a 
LPS-specific  inhibitory pathway. Thus, binding diPS to CD14 
or another molecule might initiate a negative signal that coun- 
teracts  the positive signal from LPS. 
In keeping with the results of Wright et al. (8), we also 
observed that high concentrations (10 ng/ml) of LPS par- 
tinily overcame the inhibition of NF-r.B binding activity which 
resulted from blocking LPS binding to CD14 by mAb 60b. 
Since the uptake of LPS by the 60b-treated ceils was not above 
background (nonspeciiic) binding using our radiolabeled probe, 
small amounts of LPS may have been taken up by the cells 
via non-CD14 mechanisms and then interacted with another 
molecule or molecules in the signal pathway. 
It seems likely that dLPS and LA-14-PP did not inhibit 
LPS uptake in our studies because the number of molecules 
of cell-surface CD14 greatly exceeded the number of mole- 
cules of ligand bound to the cells. By using LPS that was 
biosynthetically radiolabeled  to high specific activity (30), 
we were able to measure much smaller amounts of LPS and 
diPS than had previously been possible in studies of LPS-cell 
interactions. The picogram amounts of cell-associated LPS 
that were measured in these experiments were near the dose 
threshold for cellular responses in this in vitro system. The 
LPS uptake was equivalent to 2,250-165,000 molecules per 
cell, well below the number of CD14 molecules on the calls 
(106 or more). The great excess of call-surface CD14 thus 
provides a likely explanation for the lack of inhibition of LPS- 
LBP uptake by dLPS-LBP. R~ently, Couturier et al.  (42) 
reported binding of derivatized [3H]LPS  to human mono- 
cytes in the presence of FCS at room temperature. Binding 
appeared to be dose-dependent, saturable,  displaceable, and 
inhibitable by antibodies to CD14. Saturating amounts of 
LPS (~,1/zg added per million ceils) were much higher than 
the concentrations used in the present study (0.1-10 ng LPS 
per million cells), again suggesting that saturation of CD14 
occurs at LPS concentrations far greater than the low con- 
centrations used here. 
The present results seem most consistent with a scenario 
in which CD14 binds LPS and LPS-LBP, accumulating LPS 
on the plasma membrane where the fully acylated lipid A 
moiety can then interact with other key molecules in the re- 
sponse cascade, dips may also interact with these molecules 
but, lacking the necessary structural information (acyloxyacyl 
groups), dips is unable to initiate the signal.  The ability 
of diPS to inhibit responses to much larger amounts of LPS, 
despite the presence of a large excess of CD14 on the cells, 
suggests that the putative signaling molecules are much less 
abundant than CD14. 
The ability of preincubation with dLPS to prevent cellular 
responses to much larger amounts of LPS reinforces the sug- 
gestion (18-20) that diPS, if generated in vivo, might blunt 
responses to LPS and provide an LPS-specific mechanism for 
controlling the inflammatory response. Our findings also sug- 
gest that dips, generated intracellularly,  might play a role 
in the induction of tolerance to LPS. Finally, it is possible, 
as suggested by Kovach et al.  (23),  that part-structures of 
lipid A or LPS that lack acyloxyacyl groups could be useful 
therapeutics for gram-negative bacterial  sepsis. Our results 
provide support for all of these speculations and encourage 
further efforts  to evaluate them experimentally. 
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